CureDuchenne Ventures

CureDuchenne Ventures is the venture philanthropy arm tied to the broader CureDuchenne organization, deploying capital into biotech startups developing treatments for Duchenne muscular dystrophy. The fund occupies a deliberately narrow lane: a single inherited disease with a defined patient population, a complex therapeutic landscape spanning gene therapy, exon-skipping, and adjacent modalities, and a community of patients and families that the parent organization has spent years building relationships with. Investment activity sits within biotech and pharma therapeutics. Limited public information is available on a partner roster or detailed portfolio outside what the organization itself publishes, but the disease-specific mandate is the defining feature of the fund.

Capital is deployed at Seed and Series A stages with check sizes of $1M to $5M, positioning CureDuchenne Ventures as a meaningful early backer rather than a token participant. The Newport Beach base reflects the parent organization’s footprint rather than a particular investment cluster, and the geographic scope is effectively wherever the science is, given how few teams worldwide are advancing credible Duchenne programs. The fund’s role often complements traditional biotech investors by bringing patient-network insight and disease-specific credibility to the cap table.

Founders working on Duchenne should expect diligence that is unusually informed about the disease, the patient experience, and the regulatory and clinical realities of small specialized populations. The fund’s value extends beyond capital into trial design feedback, patient recruitment access, and standing within the Duchenne community, all of which can shape whether a program reaches approval. Teams pursuing other indications, even adjacent neuromuscular conditions, are not the right fit; the mandate is exact.